Sipilä, Lauri J.
Aavikko, Mervi
Ravantti, Janne
Martin, Samantha
Kuopio, Teijo
Lahtinen, Laura
FinnGen,
Peltomäki, Päivi
Mecklin, Jukka-Pekka
Aaltonen, Lauri A.
Seppälä, Toni T.
Funding for this research was provided by:
Research Council of Finland (312041, 312041)
Jane and Aatos Erkko Foundation
Research Council of Finland (320149)
iCAN Digital Precision Cancer Medicine Flagship
Cancer Foundation Finland
University of Helsinki
Article History
Received: 19 January 2024
Accepted: 12 May 2024
First Online: 7 June 2024
Declarations
:
: T.T.S. declares a consultation fee from Amgen Finland, Tillots Pharma and Nouscom. T.T.S is CEO and co-owner of Healthfund Finland and Clinical Advisory board member of LS Cancer Diag. P.P. is a Clinical Advisory board member of LS Cancer Diag. Other authors declare no conflicting interests.
: T.T.S. declares a consultation fee from Amgen Finland, Tillots Pharma and Nouscom. T.T.S is CEO and co-owner of Healthfund Finland and Clinical Advisory board member of LS Cancer Diag. P.P. is a Clinical Advisory board member of LS Cancer Diag. Other authors declare no conflicting interests.
: Variant validation was conducted in collaboration with Central Finland Biobank, using tissue material stored in the biobank. An ethics approval for the RETURN project has been applied for and received from The Ethics Committee of the Wellbeing Services County of Pirkanmaa (R23004B, 9/2023).